Clinical trials: Respiratory Symptoms
Cough
Benzonatate Dose Tolerance Study
This is a single-center, randomized, third party blind, placebo controlled, dose escalation study of benzonatate following single dose administration.
- Trial name
- NCT01690975
- Testing
- Benzonatate - 400 mg, Benzonatate - 600 mg
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
Study to obtain data about changing from the chlorofluorocarbon (CFC) - containing Berotec® 200 µg metered - dose inhaler to the CFC - free Berotec® N 100 µg metered - dose inhaler
- Trial name
- NCT02244216
- Testing
- Berotec® N 100 µg Metered-dose Inhaler
- Volunteers
- 2,914 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive (COPD)
Telemonitoring of Patients With COPD in Carinthia
Evaluation whether the introduction of large-scale telemonitoring of patients with COPD produces benefits in terms of reduced hospital readmissions, improved health related quality of life and health status.
- Trial name
- RenewingHealth (NCT01580072)
- Testing
- self-monitoring for patients with severe COPD, nurse-monitoring for patients with severe COPD
- Where
- 3 sites in Austria
- Volunteers
- 65 people
- Sponsor
- Landeskrankenanstalten-Betriebsgesellschaft
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to Severe…
- Trial name
- NCT07418736
- Testing
- CM326 dose 1, CM326 dose 2
- Where
- China
- Volunteers
- 318 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
COPD, Respiratory Tract Disease
Prospective, Observational Study of Wellinks Effect on COPD Hospital Readmissions
This prospective, observational study is designed to investigate clinical outcomes and collect patient feedback on the use of Wellinks, an integrated virtual chronic obstructive pulmonary disease (COPD) management solution, for…
- Conditions
- COPD, Respiratory Tract Disease, Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
- Trial name
- POWER (NCT05330507)
- Testing
- Wellinks
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Convexity Scientific Inc
Pulmonary Disease, Chronic Obstructive
Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease
Study to compare the effect of 'natural' as opposed to 'optimal' technique on the percentage of the dose received from the Respimat® inhaler and metered dose inhaler
- Trial name
- NCT02176187
- Testing
- Berodual® Respimat® inhaler, Berodual® metered dose inhaler
- Volunteers
- 3 people
- Sponsor
- Boehringer Ingelheim
COPD
The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD
This is a study examining the effect of inhaled PUL-042 on peak lower respiratory symptoms as measured by subject diary in early stage COPD subjects who are experimentally infected with rhinovirus.
- Trial name
- NCT03794557
- Testing
- Sterile Water Injection, PUL-042 Inhalation Solution
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Pulmotect, Inc.
Pulmonary Disease, Chronic Obstructive
Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation
The timing of initiating short-term treatment for COPD exacerbations with oral corticosteroids and/or antibiotic therapy has been shown to influence the recovery time of exacerbations with early initiation of exacerbation therapy…
- Trial name
- NCT01431911
- Testing
- Early maintenance treatment, Delayed Maintenance treatment
- Volunteers
- 3,806 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD
This is a 4-week, multicenter, randomized, double-blind, parallel group and active controlled study. Patients will be randomized (1 to 1 ratio) to a 4-week double-blind treatment period of either FDC (fixed-dose combination) of…
- Trial name
- NCT02683109
- Testing
- FDC of tiotropium + olodaterol, Tiotropium, Olodaterol
- Where
- 22 sites in Austria, Denmark and 3 more
- Volunteers
- 221 people
- Sponsor
- Boehringer Ingelheim
Hypoxia
OM2 Abbreviated Sensor Verification
The verification of an investigational pulse oximetry board to verify pulse rate and saturation accuracy over a specified saturation range in diverse populations.
- Trial name
- NCT06415799
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01663987
- Testing
- tiotropium bromide
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Dyspnea
Vibration Response Imaging (VRI) in Dyspnea Patients Presenting to the ED
For the patient with acute dyspnea in the ED, early differentiation between CHF and non-CHF causes is essential for proper management.
- Trial name
- NCT01206621
- Where
- 8 sites in United States, Israel
- Volunteers
- 530 people
- Sponsor
- Deep Breeze
Non-small Cell Lung Cancer (NSCLC), Cachexia
A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss
Study to investigate the effect of ponsegromab on skeletal muscle mass and physical function in adult participants with non-small cell lung cancer associated cachexia.
- Trial name
- NCT07663630
- Testing
- ponsegromab
- Where
- 7 sites in United States, China
- Volunteers
- 80 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
- Trial name
- Aspire (NCT01266265)
- Testing
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin
- Where
- 88 sites in United States
- Volunteers
- 1,333 people
- Sponsor
- United Therapeutics
COPD
A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients
The study aim is to compare the pharmacodynamic effects (cardiovascular effects- primary variable: Heart rate over 4 hours post dosing- ) after administration of BDP and formoterol administered as CHF 1535 100/6 NEXThaler DPI or…
- Trial name
- NEXThaler (NCT02000609)
- Testing
- CHF 1535 NEXThaler 800/48, CHF 1535 NEXThaler 200/12, CHF 1535 pMDI 200/12
- Where
- United Kingdom
- Volunteers
- 49 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients
There are three elements to this study: Part A: Single dose escalation in healthy subjects. 6 dose levels of QAK423 are planned in healthy volunteers. Part B: Single dose escalation in patients with mild/moderate COPD.
- Trial name
- NCT01197287
- Testing
- QAK423A
- Where
- Germany
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
COPD, Chronic Obstructive Pulmonary Disease
Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease
The objective of the Biopsy trial is to investigate the effect of roflumilast 500 µg tablets once daily versus placebo on inflammation parameters in bronchial biopsy tissue specimen and additional in sputum and blood serum.
- Trial name
- NCT01509677
- Testing
- Roflumilast
- Where
- 20 sites in Denmark, Germany and 3 more
- Volunteers
- 158 people
- Sponsor
- AstraZeneca
Metastatic Non-small Cell Lung Cancer
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients…
- Trial name
- LUNAR-2 (NCT06216301)
- Testing
- NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy
- Where
- 104 sites in United States, Austria and 15 more
- Volunteers
- 734 people
- Sponsor
- NovoCure GmbH
Advanced Solid Tumor, Lymphoma
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study.
- Conditions
- Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT04106167
- Testing
- Allogeneic natural killer (NK) cell
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fate Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.